Precision Biosciences Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Precision Biosciences Inc's ROA in the second quarter of 2026?
Precision Biosciences Inc recorded a cumulative net loss of $-53 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -40.74%.

However, within the Healthcare sector 494 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3721, from total ROA ranking in the first quarter of 2026 at 4418.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	15.59 %	15.66 %	15.35 %	-36.99 %	-31.64 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-53	-44	-46	-84	-78
Return On Assets (TTM)	-40.74 %	-34.83 %	-38 %	-72.58 %	-60.71 %
DTIL's Total Ranking	# 3721	# 4418	# 4219	# 4181	# 3503
Total Assets (TTM) in million	126	144	154	94	109
Seq. Total Assets Change	-12.49 %	-6.82 %	65.13 %	-14.15 %	-12.45 %
Seq. Net Income Change	-	-	-	-	-

DTIL's 5 Years Annual ROA >> Back to DTIL Management Effectiveness >> Compare DTIL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 64
Sector	# 495
Overall	# 3766

Return On Assets Statistics
High	Average	Low
10.06 %	-32.67 %	-72.19 %
(Jun 30 2024)		(Sep 30 2025)

Financial Statements
Precision Biosciences Inc's Assets	$ 126 million	DTIL's Balance sheet
Precision Biosciences Inc's Income	$ -33 million	Quarterly DTIL's Income Statement
DTIL's Income by Division		See DTIL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	38.12 %	-14.01 %	-35.73 %	13.61 %	43.71 %
Total Assets in million	181	131	152	237	208
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-46	7	-61	-112	-31
Annual Return On Assets	-25.3 %	5.48 %	-40.29 %	-47.15 %	-14.68 %

DTIL's 5 Years Annual ROA >> Back to DTIL Management Effectiveness >> Compare DTIL ROA to its Competitors

More Return On Assets Ratios
DTIL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DTIL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DTIL's Competitors
Subscribers only: Roa for Precision Biosciences Inc's Suppliers
Subscribers only: Return On Assets for DTIL's Customers

You may also want to know
DTIL's Roi	DTIL's Inventory Turnover Ratio	DTIL's Growth Rates	DTIL's Dividend Comparisons
	DTIL's Profitability Ratios	DTIL's Asset Turnover Ratio	DTIL's Dividend Growth
DTIL's Roe	DTIL's Valuation Ratios	DTIL's Financial Strength Ratios	DTIL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:29:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.